Crossmark

Modified EXTREME regimen versus modified TPEx regimen as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, open-label, randomized, exploratory study (TEMPER study)

Crossref DOI link: https://doi.org/10.1007/s10147-026-02964-w

Published Online: 2026-02-09

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Suzuki, Motoyuki https://orcid.org/0000-0001-9747-6993
Kishino, Akehito

Sugasawa, Masashi

Fujii, Takashi

Nakanome, Ayako

Terada, Tomonori

Hirakawa, Hitoshi

Ueki, Yushi

Matsuo, Mioko

Ito, Rie

Hotomi, Muneki

Kanno, Masafumi

Watanabe, Akihito

Kitamura, Yoshiaki

Okami, Kenji

Endo, Kazuhira

Ono, Takeharu

Hirano, Shigeru

Omura, Go

Omori, Koichi

Yamamoto, Yoshifumi

Shimokawa, Mototsugu

Inohara, Hidenori
Funding

Funding for this research was provided by:

The University of Osaka
License Information

Text and Data Mining valid from 2026-02-09

Version of Record valid from 2026-02-09
More Information

Article History

Received: 1 August 2025

Accepted: 12 January 2026

First Online: 9 February 2026

Declarations

:

: The authors declare that they have no conflict of interest.

: The study protocol was approved by the Certified Clinical Research Review Committee of the Specified Non-profit Corporation Clinical Research Network Fukuoka (certificate number: CRB7180004). Each facility participated in the trial after receiving approval from its respective hospital directors and began enrolling patients. This trial was conducted in accordance with the principles of the Declaration of Helsinki. All patients provided written informed consent prior to enrollment.

: This study was registered at the University Hospital Medical Information Network (UMIN) database (Registration No. UMIN000025436; ) on December 27, 2016 and at the Japan Registry of Clinical Trials (jRCT) (Registration No. jRCTs071180009; ) on November 29, 2018.

Document is current

Any future updates will be listed below